High quality copy number and genotype data from FFPE samples using Molecular Inversion Probe (MIP) microarrays
Author
Wang, YukerCarlton, Victoria
Karlin-Neumann, George
Sapolsky, Ronald
Zhang, Li
Moorhead, Martin
Wang, Zhigang
Richardson, Andrea
Warren, Robert
Walther, Axel
Bondy, Melissa
Sahin, Aysegul
Krahe, Ralf
Tuna, Musaffe
Thompson, Patricia
Spellman, Paul
Gray, Joe
Mills, Gordon
Faham, Malek
Affiliation
Affymetrix Inc. Santa Clara, CA, USAMD Anderson Cancer Center, Houston, TX, USA
DF/BWH Cancer Center, Boston, MA, USA
University of California San Francisco, San Francisco, CA, USA
Cancer Research UK, London Research Institute, London, UK
Arizona Cancer Center, Tucson, AZ, USA
Lawrence Berkeley National Laboratory, Berkeley, CA, USA
Issue Date
2009
Metadata
Show full item recordPublisher
BioMed CentralCitation
BMC Medical Genomics 2009, 2:8 doi:10.1186/1755-8794-2-8Journal
BMC Medical GenomicsRights
© 2009 Wang et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0).Collection Information
This item is part of the UA Faculty Publications collection. For more information this item or other items in the UA Campus Repository, contact the University of Arizona Libraries at repository@u.library.arizona.edu.Abstract
BACKGROUND:A major challenge facing DNA copy number (CN) studies of tumors is that most banked samples with extensive clinical follow-up information are Formalin-Fixed Paraffin Embedded (FFPE). DNA from FFPE samples generally underperforms or suffers high failure rates compared to fresh frozen samples because of DNA degradation and cross-linking during FFPE fixation and processing. As FFPE protocols may vary widely between labs and samples may be stored for decades at room temperature, an ideal FFPE CN technology should work on diverse sample sets. Molecular Inversion Probe (MIP) technology has been applied successfully to obtain high quality CN and genotype data from cell line and frozen tumor DNA. Since the MIP probes require only a small (~40 bp) target binding site, we reasoned they may be well suited to assess degraded FFPE DNA. We assessed CN with a MIP panel of 50,000 markers in 93 FFPE tumor samples from 7 diverse collections. For 38 FFPE samples from three collections we were also able to asses CN in matched fresh frozen tumor tissue.RESULTS:Using an input of 37 ng genomic DNA, we generated high quality CN data with MIP technology in 88% of FFPE samples from seven diverse collections. When matched fresh frozen tissue was available, the performance of FFPE DNA was comparable to that of DNA obtained from matched frozen tumor (genotype concordance averaged 99.9%), with only a modest loss in performance in FFPE.CONCLUSION:MIP technology can be used to generate high quality CN and genotype data in FFPE as well as fresh frozen samples.EISSN
1755-8794Version
Final published versionAdditional Links
http://www.biomedcentral.com/1755-8794/2/8ae974a485f413a2113503eed53cd6c53
10.1186/1755-8794-2-8
Scopus Count
Collections
Except where otherwise noted, this item's license is described as © 2009 Wang et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0).